Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 12/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CPB1 | P15086 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7904628 | 1.00 | PROKR1 (0.40) | PROKR1CNR2BTKCFDJAK2 | |
| SCHEMBL2790135 | 1.00 | PROKR1 (0.40) | PROKR1CNR2BTKCFDJAK2 | |
| SCHEMBL7891283 | 0.92 | DPP4 (0.35) | PROKR1BTKCFDJAK2JAK1 | |
| SCHEMBL2813997 | 0.92 | PROKR1 (0.38) | PROKR1BTKCFDDPP4 | |
| SCHEMBL2791457 | 0.92 | PROKR1 (0.40) | PROKR1CNR2JAK2JAK1JAK3 | |
| SCHEMBL2817352 | 0.91 | PROKR1 (0.45) | PROKR1CNR2BTKCFDJAK2 | |
| SCHEMBL7900019 | 0.91 | PROKR1 (0.39) | PROKR1BTKDPP4DPP9 | |
| SCHEMBL2792291 | 0.90 | DPP4 (0.33) | PROKR1CNR2BTKCFDJAK2 | |
| SCHEMBL2792294 | 0.90 | DPP4 (0.33) | PROKR1CNR2BTKCFDJAK2 | |
| SCHEMBL2791393 | 0.90 | BTK (0.36) | PROKR1CNR2BTKCFDCPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010111634-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |